Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck KGaA
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Tepotinib Phase II study in lung adenocarcinoma harbouring MET exon 14 (METex14) skipping alterations
To assess the efficacy of tepotinib in subjects with advanced adenocarcinoma of the lung harboring the MET exon 14 (METex14) skipping alterations, as per objective response (confirmed complete respo...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
MSB0010718C in Subjects With Skin Cancer MSB0010718C en sujetos con cancer de piel
The primary objective of the trial is to assess the clinical activity of MSB0010718C as determined by the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors versio...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Cilengitide and cetuximab in combination with platinum-based chemotherapy as first-line treatment for subjects with advanced NSCLC. Open-label, randomized, controlled, multicenter Phase II study investigating 2 cilengitide regimens in combination with cetuximab and platinum-based chemotherapy (cisplatin/vinorelbine or cisplatin/gemcitabine) compared to cetuximab and platinum-based chemotherapy alone as first-line treatment for patients with advanced NSCLC (CERTO)
Progression free survival time
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
An open-label, randomised, phase II study in subjects with extensive disease, small cell lung cancer (ED-SCLC) after an initial response (complete response or partial response) to platinum-based therapy to determine the effect of EMD 273066 following low-dose cyclophosphamide on disease progression and survival versus best supportive care alone. Estudio en fase abierta, aleatorizado, de fase II en sujetos con enfermedad avanzada, en cáncer de pulmón microcítico (CPM), después de una respuesta inicial (respuesta completa o parcial) a una terapia basada en platino, para evaluar el efecto de EMD 273066 tras dosis bajas de ciclofosfamida sobre la progresión de la enfermedad y la supervivencia frente a la mejor terapia de soporte
El objetivo principal de este estudio es determinar si la exposición al EMD 273066 aumenta la proporción de sujetos con -Supervivencia sin progresión (SSP) seis meses después de la aleatorización
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naïve Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
To evaluate progression-free survival time of subjects treated with EMD 1201081 + cetuximab compared to cetuximab alone in cetuximab-naïve subjects with recurrent and/or metastatic SCCHN who have prog...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Phase II Trial of AS902330 as Adjunct to Microfracture in Cartilage Injury
The primary objective is to evaluate the effect of AS902330 intra-articular (i.a.) knee injections as adjunct to microfracture (MFx) surgery on the composition of the refilled cartilage in the target ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
2
3
4
5
6
7